- Home
- PRG vs TNGX Comparison
PRG vs TNGX Comparison
Compare PRG & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PRG | TNGX |
|---|---|---|
| Founded | 2020 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.5B |
| IPO Year | 2020 | 2020 |
Fundamental Metrics
Financial Performance| Metric | PRG | TNGX |
|---|---|---|
| Price | $28.12 | $17.30 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 7 | 9 |
| Target Price | ★ $47.50 | $18.75 |
| AVG Volume (30 Days) | 563.1K | ★ 3.4M |
| Earning Date | 01-01-0001 | 06-01-2026 |
| Dividend Yield | ★ 1.82% | N/A |
| EPS Growth | N/A | ★ 26.89 |
| EPS | ★ 3.59 | N/A |
| Revenue | ★ $2,409,223,000.00 | $62,384,000.00 |
| Revenue This Year | $25.27 | N/A |
| Revenue Next Year | $6.59 | $13.81 |
| P/E Ratio | $7.97 | ★ N/A |
| Revenue Growth | N/A | ★ 48.29 |
| 52 Week Low | $23.50 | $1.04 |
| 52 Week High | $41.14 | $17.63 |
Technical Indicators
Market Signals| Indicator | PRG | TNGX |
|---|---|---|
| Relative Strength Index (RSI) | 29.16 | 72.25 |
| Support Level | $27.39 | $10.90 |
| Resistance Level | $30.61 | $17.63 |
| Average True Range (ATR) | 1.45 | 1.15 |
| MACD | -0.95 | 0.45 |
| Stochastic Oscillator | 0.00 | 95.02 |
Price Performance
Historical ComparisonAbout PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated to discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. It is currently developing two MTA-cooperative PRMT5 inhibitors; TNG462 for non-CNS cancers, including pancreatic and lung cancer, and TNG456, a next-generation, brain-penetrant PRMT5 inhibitor, for CNS cancers, including GBM. Its pipeline products are PRMT5 and CoREST.